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Exactly a 100 years ago, the discovery of a cancer-causingvirus by Rous1 laid the foundations for research on the
molecular basis of cancer. Initially, this finding was met with
considerable skepticism; however, subsequent work on Rous
sarcoma virus led to the discovery of the first known cancer-
associated molecular alteration, the proto-oncogene c-src.2,3
Since then, we have come a long way in our understanding of
the molecular alterations that drive cancer. Identifying and
targeting the key driver molecular alterations has led to the
development of some remarkably effective therapies against
cancer. The development of imatinib for the treatment of
chronic myelogenous leukemia and trastuzumab for breast
cancer opened a new era in the treatment of cancer.
In the past decade, a number of clinical trials with
molecularly targeted drugs in the treatment of lung cancer
and particularly in non-small cell lung cancer (NSCLC).
However, only a few of the targeted therapies have shown
promise in the treatment of lung cancer. In the 11th annual
meeting of molecularly targeted therapy in NSCLC, a number
of molecularly targeted drugs were discussed. Given the large
number of targeted therapies under evaluation, it is important
to reflect on our past experience with targeted therapies and
identify lessons that are relevant for effective drug develop-
ment in future. On the basis of our review of the past
successes and failures with targeted therapy in cancer, we
have identified the following key points that would be of
relevance to future drug development in lung cancer.
Target Should be a Critical Determinant for
Growth and Survival of Cancer Cells
The identification of high expression levels of c-kit and
its ligand stem cell factor (SCF) in small cell lung cancer
(SCLC) and subsequent clinical trials with imatinib for the
treatment of patients with SCLC is a relevant example for this
dictum.4 Coexpression of SCF and c-kit suggested an auto-
crine loop that promotes cell proliferation.5 These findings
led to the evaluation of imatinib a c-kit inhibitor in the
treatment of patients with SCLC either as a single agent or in
combination with cytotoxic chemotherapy; however, these
trials failed to show meaningful therapeutic benefit from
imatinib treatment.6–8 Subsequent studies identified that SCF
stimulation of c-kit played only a minor role in cell prolifer-
ation, and there were several other signaling pathways that
maintained tumor cell proliferation, in the absence of the
SCF/c-kit activation.9 Inactivation of the retinoblastoma (Rb)
gene makes the SCF/C-kit/mitogen-activated protein kinase
pathway for proliferation redundant in SCLC.10 Hence, it is
important to identify if a potentially targetable molecular
alteration has a dominant role in the maintenance and pro-
gression of the malignant phenotype. This requires well-
designed, hypothesis-driven functional studies to establish
the role of a specific molecular target in cancer.
Use of Molecularly Targeted Therapies in
“Targeted” Population
Promising preclinical findings with novel targeted
agents do not always translate into improved outcomes in the
clinic. Biomarker identification and patient selection are cru-
cial for optimal drug development. Patients with treatment
refractory NSCLC who were positive for the EML4-ALK
fusion gene had a response rate of 57% after treatment with
crizotinib.11 Similarly, treatment with vemurafenib, a BRAF
inhibitor, resulted in an 81% response rate in 38 patients with
malignant melanoma whose tumor cells harboring BRAF
mutations.12 Every attempt should be made to identify pre-
dictive biomarkers using innovative approaches and emerg-
ing technologies. As always, studies should be thoughtfully
designed and tissue collection should be made mandatory.13
Empiric Combination Regimens Are Unlikely to
be Successful
Empiric combinations of chemotherapeutic agents and
targeted drugs have proven to be unsuccessful in unselected
patients with NSCLC. Attempts have been made to build on the
efficacy of standard front-line platinum doublet therapy with the
addition of a molecularly targeted agent. In this context, the
epidermal growth factor tyrosine kinase inhibitors have been the
most extensively studied in combination with chemotherapy in
patients with previously untreated NSCLC. Two randomized
phase III trials evaluating the combination of erlotinib- and
platinum-based front-line chemotherapy failed to demonstrate a
survival benefit.14,15 Similarly, the combination of gefitinib and
front-line platinum-doublet therapy did not show any improve-
ment in survival compared with chemotherapy alone.16–19
It has become increasingly clear that such trials are
likely to fail, whereas mechanistically sound combinations,
targeting specific population subsets, are more likely to suc-
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ceed. In fact only 3 of 15 (20%) published phase III trials
evaluating empiric combination of targeted drugs and plati-
num doublet chemotherapy in the front-line treatment of
NSCLC met their primary end points (Table 1). In fact, one
of the phase III studies amended their original primary end
point from overall survival to progression-free survival22 and
in another the drug combination failed to meet its primary end
point in a separate phase III trial20,21; if those two phase III
studies are excluded, then the success rate is even lower
(6.7%).
Beware of Unexpected Toxicities
The combination of bevacizumab and chemoradiation
for limited stage SCLC and locally advanced NSCLC has
resulted in the development of trachea-esophageal fistula.31
Another case in point is cediranib, an inhibitor of all three
VEGF receptors, which showed encouraging tumor control in
the phase I setting, when used at the doses of 30 mg and 45
mg, in combination with platinum-based chemotherapy in
patients with advanced NSCLC. In this study, partial re-
sponses were seen in 9 of the 20 enrolled patients, whereas 11
patients had stable disease.32 Nevertheless, in the phase II/III
double-blinded trial of carboplatin and paclitaxel with either
cediranib or placebo at these doses resulted in excessive
treatment-related toxicities and mortality in the cediranib
arm.33 Patients treated with cediranib experienced a higher
rate of serious adverse events, fatal events, hospitalizations,
and death within 30 days of last dose of study drug. Hyper-
tension, hypothyroidism, hand-foot syndrome, and gastroin-
testinal toxicity were more commonly seen in the patients
treated with cediranib. Consequently, a trial using a lower
dose of cediranib (20 mg) or placebo along with carboplatin
and paclitaxel is underway.
CONCLUSION
Targeted therapies hold considerable promise in the
treatment of patients with lung cancer. Nevertheless, success
lies in our ability to learn from our previous experience and
implement those lessons in our future plans for targeted drug
development against lung cancer.
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